Insights from 2024 EHA Annual Meeting
Video Player is loading.
10 seconds
Playback speed
EHA 2024 Insights: Final 5-Year Results of Olutasidenib for Mutated IDH1 AML
By
Insights from 2024 EHA Annual Meeting
FEATURING
Jorge Cortés
By
Insights from 2024 EHA Annual Meeting
FEATURING
Jorge Cortés
Comments 0
Login to view comments.
Click here to Login
